RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Kangmei Pharmaceutical Co Stock

Kangmei Pharmaceutical Co Equity 2024

Kangmei Pharmaceutical Co Equity

7.05 B CNY

Ticker

600518.SS

ISIN

CNE0000017M1

In 2024, Kangmei Pharmaceutical Co's equity was 7.05 B CNY, a 1.43% increase from the 6.95 B CNY equity in the previous year.

Kangmei Pharmaceutical Co Aktienanalyse

What does Kangmei Pharmaceutical Co do?

Kangmei Pharmaceutical Co. Ltd is a Chinese company that was founded in 1997. It is headquartered in the city of Lianyungang in the Jiangsu province and has been listed on the Shanghai Stock Exchange since 2001. With a market capitalization of over 15 billion US dollars, it is one of the leading pharmaceutical companies in the country. The company's business model is based on the development, production, and distribution of pharmaceutical products and medical devices. It is divided into several divisions, including drugs for colds, diabetes, cancer, and other diseases, dietary supplements, contrast agents for X-rays, as well as medical devices such as infusion pumps, blood pressure monitors, and ultrasound machines. Kangmei has focused heavily on the domestic market in recent years and is present in all provinces of China. It operates over 30 subsidiaries throughout the country and has more than 10,000 employees. The company is committed to improving healthcare in China and developing innovative products for the domestic market. One of Kangmei's most well-known drugs is "Ganmaoling Granule," a traditional Chinese medicine for treating colds and flu. It has been in production for over 30 years and is very popular in China. Kangmei also produces various drugs for the treatment of diabetes, including insulin preparations and oral medications. Another important area for Kangmei is the development of cancer drugs. The company specializes in researching and developing innovative therapies for various types of cancer. It has introduced several products to the market that can be used in the treatment of lung cancer, breast cancer, and other tumors. In addition to its pharmaceutical products, Kangmei has also developed a range of dietary supplements, such as "Qingkailing Capsules," which are made from natural ingredients and are intended to strengthen the immune system. These products are very popular in China and also contribute to Kangmei's diversification of its business operations. Kangmei has also specialized in the production of medical devices. It has developed a wide range of products such as infusion pumps, dialysis machines, and ultrasound devices. These devices are in high demand in China and other countries around the world, such as Africa and Latin America. Overall, Kangmei has established a strong presence in the Chinese pharmaceutical and medical market and is well-positioned to benefit from the strong growth of the healthcare sector in China. The company focuses on innovation and invests heavily in research and development of new products. It aims to play a leading role in the Chinese healthcare industry while contributing to the improvement of healthcare services. Kangmei Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Kangmei Pharmaceutical Co's Equity

Kangmei Pharmaceutical Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Kangmei Pharmaceutical Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Kangmei Pharmaceutical Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Kangmei Pharmaceutical Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Kangmei Pharmaceutical Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Kangmei Pharmaceutical Co stock

What is the equity of Kangmei Pharmaceutical Co this year?

Kangmei Pharmaceutical Co has equity of 7.05 B CNY this year.

What was the equity of Kangmei Pharmaceutical Co compared to the previous year?

The equity of Kangmei Pharmaceutical Co has increased/decreased by 1.43% increased compared to the previous year.

What impact does a high equity have on investors of Kangmei Pharmaceutical Co?

A high equity is advantageous for investors of Kangmei Pharmaceutical Co as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Kangmei Pharmaceutical Co?

A low equity can be a risk for investors of Kangmei Pharmaceutical Co, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Kangmei Pharmaceutical Co affect the company?

An increase in equity of Kangmei Pharmaceutical Co can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Kangmei Pharmaceutical Co affect the company?

A reduction in equity of Kangmei Pharmaceutical Co can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Kangmei Pharmaceutical Co?

Some factors that can affect the equity of Kangmei Pharmaceutical Co include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Kangmei Pharmaceutical Co so important for investors?

The equity of Kangmei Pharmaceutical Co is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Kangmei Pharmaceutical Co take to change the equity?

To change equity, Kangmei Pharmaceutical Co can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Kangmei Pharmaceutical Co pay?

Over the past 12 months, Kangmei Pharmaceutical Co paid a dividend of 0.02 CNY . This corresponds to a dividend yield of about 1.14 %. For the coming 12 months, Kangmei Pharmaceutical Co is expected to pay a dividend of 0 CNY.

What is the dividend yield of Kangmei Pharmaceutical Co?

The current dividend yield of Kangmei Pharmaceutical Co is 1.14 %.

When does Kangmei Pharmaceutical Co pay dividends?

Kangmei Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of June, July, August, September.

How secure is the dividend of Kangmei Pharmaceutical Co?

Kangmei Pharmaceutical Co paid dividends every year for the past 0 years.

What is the dividend of Kangmei Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Kangmei Pharmaceutical Co located?

Kangmei Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kangmei Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kangmei Pharmaceutical Co from 8/28/2019 amounting to 0.024 CNY, you needed to have the stock in your portfolio before the ex-date on 8/28/2019.

When did Kangmei Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 8/28/2019.

What was the dividend of Kangmei Pharmaceutical Co in the year 2023?

In the year 2023, Kangmei Pharmaceutical Co distributed 0 CNY as dividends.

In which currency does Kangmei Pharmaceutical Co pay out the dividend?

The dividends of Kangmei Pharmaceutical Co are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Kangmei Pharmaceutical Co

Our stock analysis for Kangmei Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kangmei Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.